卡培他滨和氟尿嘧啶的毒副作用相似。
Toxic effects of capecitabine and fluorouracil were similar.
目的分析比较卡培他滨的几种基本的合成路线。
Aim To analyze and compare different syntheses of capecitabine.
在这些患者中舒尼替尼和卡培他滨的剂量逐步递增。
Sunitinib and capecitabine doses were escalated in serial patient cohorts.
吉西他滨和卡培他滨的组合有时用来治疗转移性肾细胞癌。
A combination of gemcitabine and capecitabine is sometimes used to treat metastatic renal cell cancer.
目的评价紫杉醇联合卡培他滨治疗晚期乳腺癌的疗效和毒副作用。
Objective to evaluate the therapeutic effects and toxicities of paclitaxel and capecitabine combination regimen in the treatment of advanced breast cancer.
目的：提供卡培他滨治疗消化道恶性肿瘤的药物经济学评价依据。
OBJECTIVE:To provide some basis for the evaluation of the pharmacoeconomic value of capecitabine in the treatment of digestive malignant tumor.
厄罗替尼布联合卡培他滨同样用于一线药物吉西他滨治疗失败的患者。
Erlotinib is also being evaluated in combination with capecitabine in patients who failed first-line therapy with gemcitabine.
方法：比较卡培他滨与经典MAYO方案在临床疗效和医疗费用方面的特点。
METHODS:The characteristics of therapeutic effect and medical cost were compared between capectabine and classical MAYO program.
目的观察吉西他滨联合卡培他滨治疗蒽环类耐药性晚期乳腺癌的疗效与毒性反应。
Objective To observe the results of gemcitabine combined with capecitabine on anthracycline-resistant breast cancer.
结论：紫杉醇、顺铂、卡培他滨三药联合一线治疗晚期胃腺癌的疗效和安全性均好。
Conclusions: Paclitaxel combined with cisplatin and capecitabine as the first-line treatment in patients with advanced gastric adenocarcinoma is safe and effective.
为此，本研究探讨加速分割放疗同步卡培他滨化疗治疗晚期鼻咽癌的疗效和毒副反应。
In this study, the efficacy and toxicity of accelerated fractionated radiotherapy with concurrent capecitabin chemotherapy for advanced NPC were investigated.
这个研究结果表明：服用拉帕替尼和卡培他滨获得更为显著地治疗效果，延迟了肿瘤的生长。
That study revealed that women who took Tykerb in combination with capecitabine were significantly more likely to respond positively to treatment and to experience a delay in tumor growth.
目的：探讨卡培他滨联合沙利度胺治疗晚期结直肠癌的近期疗效及癌组织胸苷磷酸化酶的表达。
Objective: To study the efficacy of combined capecitabine with thalidomide in treatment of advanced colorectal cancer and expression of thymidine phosphorylase in colorectal cancer tissue.
卡培他滨是一种新型口服氟尿嘧啶类药物，目前广泛用于乳腺癌、胃肠道肿瘤及头颈部肿瘤的治疗。
Capecitabine is a new oral drug of Fluorouracil (FU), which is widely used in the therapy of breast, gastrointestinal, head and neck cancer.
经过平均2.4年的随访，与常规化疗组相比，卡培他滨治疗组有超过两倍的复发率和两倍的死亡率。
After a median follow-up of 2.4 years, patients on capecitabine were more than twice as likely to have a relapse and twice as likely to die as those receiving standard chemotherapy.
另外，卡培他滨也可与其他药物联合应用，其联合化疗方案正在一项大型II I期临床中进行评估。
In addition, capecitabine has been combined with other drugs and is undergoing an investigation in a large phase III trial.
结论：卡培他滨和奥沙利铂用于先前未经治疗的食管癌和胃癌患者，效果分别与氟尿嘧啶和顺铂相同。
Conclusions Capecitabine and oxaliplatin are as effective as fluorouracil and cisplatin, respectively, in patients with previously untreated esophagogastric cancer.
方法66例晚期结肠癌患者按随机数字表法分为口服卡培他滨组和静脉用5-氟尿嘧啶组，每组33例。
Methods 66 patients with advanced stage of colon carcinoma were randomly divided into two groups, with 33 cases in each group.
在一项正在进行采用ECF作为对照方案的重要研究中，研究者用卡培他滨取代5 -FU或用奥沙利铂取代顺铂。
In an important ongoing study with the ECF regimen as the reference regimen, 5-fu is replaced by capecitabine and cisplatin by oxaliplatin.
与卡培他滨有关的不良反应主要为手足综合征（54.6%）、腹泻（27.3%）、中性粒细胞减少（18.2%）。
The adverse events in the combined therapy were hand-foot-syndrome(54.6%), diarrhea(27.3%), and neutropenia(18.2%), mainly due to capecitabine.
该研究计划入组600例食道癌、贲门癌和胃癌患者，早期的缓解率数据有益于应用含卡培他滨和奥沙利铂的患者，但这只是初步的结果。
This study intends to accrue 600 patients with esophagus, GE-junction, and stomach cancer. Early response data favor the use of capecitabine and oxaliplatin, but the data are preliminary .
该研究计划入组600例食道癌、贲门癌和胃癌患者，早期的缓解率数据有益于应用含卡培他滨和奥沙利铂的患者，但这只是初步的结果。
This study intends to accrue 600 patients with esophagus, GE-junction, and stomach cancer. Early response data favor the use of capecitabine and oxaliplatin, but the data are preliminary .
应用推荐